Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Welldorm Elixir

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Chloral hydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Chloral hydrate
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Welldorm Elixir contains chloral hydrate, which is one of a group of medicines called hypnotics (sleep inducing drugs). Adults: Welldorm Elixir is used for the short-term (maximum 2 weeks) treatment of severe sleeplessness (insomnia) which is interfering with normal daily life and where non-drug therapies (such as behavioural therapy and sleep hygiene) and other drugs have failed. Welldorm Elixir should be used in addition to non-drug therapies. Children and adolescents aged 2 years and above: Welldorm Elixir is used for the short-term (maximum 2 weeks) treatment of severe sleeplessness (insomnia) in children and adolescents with suspected or definite disorders that affect the development of the neurological system and brain (neurodevelopmental disorder). It is only used when the sleeplessness interferes with normal daily life and other therapies (non-drug therapies and other drugs) have failed. Welldorm Elixir should be used in addition to behavioural therapy and sleep hygiene management. The use of Welldorm Elixir in children and adolescents is not generally recommended and if used should be under the supervision of a medical specialist.

What you need to know before you take it

e Welldorm Elixir Do not take Welldorm Elixir if you:

  • are allergic to chloral hydrate or any of the other ingredients of this medicine (see section 6)
  • have severe liver or kidney problems
  • have severe heart problems
  • suffer from porphyria (an inherited blood disorder)
  • have active inflammation of the stomach or gullet (gastritis or oesophagitis), a stomach or gut ulcer or perforation of the stomach or gut wall
  • are pregnant or breast feeding. Do not give to a child under 2 years of age.

1 uk-pil-Welldorm Elixir

Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Welldorm Elixir:

  • if you are elderly or frail (weak),
  • if you have mild or moderate kidney impairment,
  • if you have mild or moderate liver impairment,
  • if you suffer from alcoholism or drug addiction problems,
  • if you have dependency to sleep medications,
  • if you have had inflammation of the stomach or gullet (gastritis or oesophagitis), an ulcer in the stomach or the gut (gastric or duodenal ulcer) or perforation of the stomach or gut wall in the past,
  • if you have heart disease or heart rhythm abnormalities (including so called QT prolongation seen with ECG monitoring),
  • if you have low potassium or magnesium levels. Other medicines and Welldorm Elixir Tell your doctor or pharmacist if you are taking, or have recently taken or might take any other medicines.: It is important to tell your doctor if you are taking any of the following:
  • sleep medication and tranquilisers (sedatives, hypnotics),
  • medicines to thin your blood (such as Warfarin),
  • medicines for depression or nervous disorders,
  • medicines intended to reduce muscle spasms,
  • medicines that affect the heart rhythm, such as medicines for heart rhythm abnormalities, medicines against malaria, some medicines against allergies (antihistamines), medicines to treat certain mental health disorders (antipsychotics) and medicines that lower potassium or magnesium levels (diuretics). Taking Welldorm Elixir with food and drink and alcohol Alcohol can increase the sedative effect of chloral hydrate. Alcohol should therefore be avoided whilst taking this medicine. Welldorm Elixir should be taken with water or milk. Pregnancy and breast feeding Welldorm Elixir should not be taken if you are pregnant or trying to become pregnant or you are breast feeding. Driving and using machines Please note that your ability to drive or operate hazardous machinery may be impaired by drowsiness as a result of taking Welldorm Elixir. Ask your doctor whether you may drive or operate machines. Important information about some of the ingredients of Welldorm Elixir Welldorm Elixir contain the following:
  • Glycerol which may cause headache, stomach upset and diarrhoea.
  • This medicine contains 23.17 g glucose per dose. This should be taken into account in patients with diabetes mellitus.
  • This medicine contains 6.3 mg of Sodium Benzoate in each 5 mL, which is equivalent to 1.26 mg /mL
  • This medicine contains 18.39 mg propylene glycol in each 5 ml which is equivalent to 3.678 mg/ ml. If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if they use other medicines that contain propylene glycol or alcohol.
  • This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, which is to say it is essentially 'sodium-free'. 2 uk-pil-Welldorm Elixir

Laboratory Tests If you are having blood tests for your thyroid, tell your doctor or nurse that you are taking this medicine, as chloral hydrate may interfere with these tests.

How to take it

Welldorm Elixir Always take Welldorm Elixir exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. For Welldorm Elixir to work successfully, your doctor will need to identify the most appropriate dose for treating your sleeplessness. A higher strength Chloral Hydrate Oral Solution is available (500mg/5ml). Your doctor will help you to select the most appropriate strength and dose. Welldorm Elixir should be administered as a single daily dose, 15-30 minutes before bedtime, with water or milk. The usual recommended doses for Welldorm Elixir are: Adults and Children aged 12 years and over and the Elderly: The usual starting dose in 430-860 mg (15-30 ml of the 143mg/5ml strength). In the frail elderly or patients with liver problems a smaller dose may be required. Not more than 70 ml of the 143mg/5ml strength Welldorm Elixir (equivalent to 2 g of Chloral Hydrate) should be taken in any one day. Children 2 – 11 years: The use of Welldorm Elixir in children and adolescents is not generally recommended and if used should be under the supervision of a medical specialist. The dose will be calculated by your doctor or pharmacist based on the weight of the child. You should follow their instructions. Not more than 35 ml of the 143mg/5ml strength Welldorm Elixir (equivalent to 1 g of Chloral Hydrate) should be taken in any one day. If you are unsure about how to take your medicine, ask your doctor or pharmacist. Duration of treatment and stopping treatment Welldorm Elixir is usually prescribed for the short term treatment of sleeping problems when other non-medication treatments (e.g. behavioural therapy and sleep hygiene) have failed, for a maximum treatment period of 2 weeks. Repeat courses of Welldorm Elixir are not recommended and can only be administered following medical specialist re-assessment, because there is a risk of abuse and dependence. If you take Welldorm Elixir over a long period of time, you may find that the medicine takes longer to work and the effect does not last for as long. This is called "tolerance" to the chloral hydrate ingredient. If you find you are becoming "tolerant" to Welldorm Elixir do not increase the amount you take. Speak to your doctor. Following prolonged treatment with Welldorm Elixir the dose should be slowly reduced before discontinuation, because there is a risk of withdrawal symptoms. Suddenly stopping Welldorm Elixir may cause delirium (severe confusion). Contact your doctor before you stop taking the medicine, as they will advise you how to stop. If you take more Welldorm Elixir than you should In the event of an accidental overdose, contact your nearest hospital casualty department or tell your doctor immediately. It is advisable to have the medicine in its original packaging available for the doctor or hospital. Signs of an overdose include, vomiting, breathing problems, abnormal heartbeat, abnormally low body temperature, pinpoint pupils, low blood pressure or coma. If you forget to take Welldorm Elixir 3 uk-pil-Welldorm Elixir

If you have missed one dose, this dose should be omitted, and the next dose should be taken at the usual time. Do not take a double dose to make up for a forgotten dose.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking the medicine and seek urgent medical advice if you have: • • • • •

Hypersensitivity and allergic reactions such as itchy skin, skin redness and swelling and skin rash, sudden wheezing, swelling of the face, lips, tongue, throat, or body, rash, fainting or difficulty breathing or swallowing. Difficulty in breathing (dyspnoea) or very slow and/or shallow breathing (respiratory depression), Heart problems such as slow, fast or irregular heartbeat (which might reflect serious heart problems such as QTc prolongation) Sudden or severe confusion (delirium) Kidney injury with symptoms such as reduced urine output

Tell your doctor if you notice any of the following side effects or notice any other effects not listed: • • • • • • • • •

Headache Mental side effects such as anxiety, restlessness, excitation or confusion Loss of coordination of muscle movements (ataxia) Stomach and intestinal problems such as abdominal pain, distension of the abdomen, flatulence, nausea and vomiting (as these might reflect serious problems such as stomach irritation, gastric necrosis, gastric perforation or gut swelling) Long-term use of this medication leading to tolerance (usual doses not producing the desired effect) Dependence on the medication and its abuse Chronic intoxication with mental symptoms or any other symptoms described here Withdrawal symptoms which may be severe and include hallucinations and delirium Ketonuria (a condition in which ketone bodies are present in the urine) detected by tests as advised by your doctor

If you are elderly you may be more susceptible to confusion and co-ordination problems which may lead to falls and injury. In new-borns and children <2 years of age, there is an increased risk of side effects. Do not give to a child under 2 years of age. If any of the symptoms become troublesome, or if you notice anything else not mentioned here, please go and see your doctor. He/she may want to adjust the dose or give you a different medicine. Reporting of side effects If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting the side effects you can help provide more information on the safety of this medicine.

How to store it

Welldorm Elixir Store below 25oC. Keep the bottle upright in the outer carton to protect from light. Use within 28 days of opening Keep this medicine out of the sight and reach of children. 4 uk-pil-Welldorm Elixir

Do not use Welldorm Elixir after the expiry date which is stated on the bottle label and carton after "EXP". The expiry date refers to the last day of the month. Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

Contents of the pack and other information

What Welldorm Elixir contain The active substance in Chloral Hydrate Oral Solution is chloral hydrate. Chloral Hydrate Oral Solution also contains glycerol (E 422), liquid glucose, sodium benzoate (E 211), sodium citrate (E 331), citric acid monohydrate (E 330), saccharin sodium (E 954), essence of passion fruit (containing natural flavouring, artificial flavouring, propylene glycol (E1520)), and purified water. What Welldorm Elixir look likes and contents of the pack Welldorm elixir is a clear, solution with a fruity odour containing 143.3 mg chloral hydrate per 5 ml. A pack size of 150 ml is available. Marketing Authorisation Holder Marlborough Pharmaceuticals Ltd, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kingdom Manufacturer LABORATORIUM SANITATIS, S.L. Leonardo da Vinci, 11 Parque Tecnológico de Álava, Miñano, 01510 Alava Spain Waymade PLC Sovereign House, Miles Gray Road, Basildon, Essex SS14 3FR. United Kingdom The Product Licence number is PL 23138/0016.

For information in large print tape, CD or Braille, telephone 01279 406759 This leaflet was last revised in April 2022.

5 uk-pil-Welldorm Elixir

Frequently asked questions about Welldorm Elixir

What is the active substance in Welldorm Elixir?

The active substance in Welldorm Elixir is chloral hydrate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Welldorm Elixir, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Welldorm Elixir without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Chloral hydrate (3 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Adults:

Chloral Hydrate Oral Solution is indicated for the short-term treatment (maximum 2 weeks) of severe insomnia which is interfering with normal daily life and where other therapies (behavioural and pharmacologic) have failed.

Chloral Hydrate Oral Solution should be used as an adjunct to non- pharmacological therapies.

Children and adolescents aged 2 years and above:

Chloral hydrate Oral Solution is indicated for short-term treatment (maximum 2 weeks) of severe insomnia in children and adolescents with suspected or definite neurodevelopmental disorder, when the insomnia is interfering with normal daily life and other therapies (behavioural and pharmacologic) have failed.Treatment should be as an adjunct to behavioural therapy and sleep hygiene management.

The use of Chloral Hydrate Oral Solution in children and adolescents is not generally recommended and if used should be under the supervision of a medical specialist.

4.2. Posology and method of administration

Conditions for use

The treatment should be as short as possible and should not exceed the maximum treatment period of 2 weeks.

Repeat courses of chloral hydrate are not recommended and can only be administered following medical specialist re-assessment, since the risk of abuse and dependence increases with the duration of treatment (see section 4.4).

Following prolonged treatment with chloral hydrate the dose should be slowly tapered before discontinuation.

The use of Chloral Hydrate Oral Solution in children and adolescents is not generally recommended and if used should be under the supervision of a medical specialist (see section 4.1).

Posology

Chloral Hydrate 143mg/5ml Oral Solution should be administered as a single daily dose, between 15 to 30 minutes before bedtime with water or milk.

Adults:

The usual dose is 430-860 mg (15-30 ml of the 143mg/5ml strength). Higher doses should not exceed a maximum of 2 g chloral hydrate (70 ml of the 143mg/5ml strength) per dose.

Elderly:

Dosage as for adults, except for the frail elderly or those with hepatic impairment where a reduction in dose may be appropriate (see section 4.4).

Paediatric population

Children 12 years and over:

The usual dose is 430-860 mg (15-30 ml of the 143mg/5ml strength). Higher doses should not exceed a maximum of 2 g chloral hydrate (70 ml of the 143mg/5ml strength) per dose.

Children (between 2 and 11 years):

30-50 mg/kg (1-1.75 ml/kg of the 143mg/5ml strength) of bodyweight. The dose should not exceed 1 g chloral hydrate (35 ml of the 143 mg/5ml strength) per dose.

Children under 2 years:

Chloral hydrate should not be used because the safety and efficacy of chloral hydrate in children aged under 2 years has not been established (see sections 4.4).

Hepatic impairment:

Chloral hydrate is contraindicated in patients with severe hepatic impairment (see section 4.3). Specific guidelines for dosage adjustments in mild and moderate hepatic impairment are not available; chloral hydrate is extensively metabolized by the liver and, therefore, dose adjustments may be warranted.

Renal impairment:

Chloral hydrate is contraindicated in patients with renal failure or severe renal impairment (see section 4.3). Specific guidelines for dosage adjustments in mild and moderate renal impairment are not available; dose adjustments may be warranted.

Method of administration

Oral.

Chloral Hydrate 143mg/5ml Oral Solution does not require dilution.

4.3. Contraindications

- Hypersensitivity to chloral hydrate or to any of the excipients listed in section 6.1.

- in patients with severe hepatic impairment,

- in patients with severe renal impairment,

- in patients with severe cardiac disease,

- in patients with active gastritis, oesophagitis, gastric or duodenal ulcers or perforation,

- in patients susceptible to acute attacks of porphyria.

4.4. Special warnings and precautions for use

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2).

Tolerance, dependence, withdrawal, misuse

Tolerance, dependence and withdrawal symptoms have been reported with chloral hydrate. Abrupt discontinuation should not be undertaken in patients receiving prolonged treatment with chloral hydrate. Sudden withdrawal of the drug may cause delirium and hallucinations. Slowly withdraw chloral hydrate.

Individuals with a history of alcohol or drug abuse or dependence may be at greater risk for abuse and misuse of chloral hydrate. Prior to prescribing chloral hydrate, each patient's risk for abuse or misuse should be assessed and patients receiving chloral hydrate should be monitored for the development of behaviours or conditions of abuse or misuse while on therapy.

Gastrointestinal disorders

Chloral hydrate should be used with caution in patients with history of gastritis, oesophagitis, gastric or duodenal ulceration or perforation. Chloral hydrate is contraindicated in patients with active gastritis, oesophagitis, gastric or duodenal ulcers or perforation (see section 4.3).

Hepatic and renal impairment

Chloral hydrate should be used with caution in patients with mild to moderate hepatic and renal impairment and is contraindicated in patients with severe hepatic and renal impairment (see sections 4.2 and 4.3).

Elderly patients

Elderly patients are more likely to experience the undesirable effects of hypnotics such as ataxia and confusion which may lead to falls and injury. For use in the frail elderly, it is recommended that the lowest effective dose be administered (see section 4.2 and 4.5).

QT prolongation

Chloral hydrate should be used with caution and particular care in patients with low potassium levels, bradyarrhythmia, congenital long QT syndrome and other heart disorders (especially arrhythmia) (see sections 4.5 and 4.8).

Paediatric population

Due to immaturity of hepatic metabolism in neonates and children <2 years of age, there is a risk of extended half-life of chloral hydrate and increased risk of undesirable effects (see section 5.2).

Excipient warnings in the formulation

Liquid Glucose: Patients with rare glucose-galactose malabsorption should not take this medicine.

Sodium benzoate: This medicine contains 6.3 mg of sodium benzoate in each 5 ml, which is equivalent to 1.26 mg/ml. Sodium benzoate may increase bilirubinaemia in neonates, resulting in neonatal jaundice which may develop into kernicterus.

Propylene glycol: This medicine contains 18.39 mg propylene glycol in each 5 ml which is equivalent to 3.678 mg/ ml. Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce serious adverse effects in neonates.

Glycerol: May cause headache, stomach upset and diarrhoea.

This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, which is to say it is essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

No formal assessments of pharmacokinetic interactions between chloral hydrate and other therapeutic medicinal products have been conducted.

Concomitant use of alcohol and chloral hydrate may potentiate the sedative effect; concomitant use should be avoided.

In combination with CNS depressants an enhancement of the central depressive effect may occur. Concomitant use with antipsychotics, hypnotics, anxiolytics/sedatives, antidepressant agents, centrally acting muscle relaxants, narcotic analgesics, anti-epileptic drugs, anaesthetics and sedative antihistamines should be avoided.

The concomitant use of drugs that also prolong the QT interval in ECG (for example, antiarrhythmics of Class IA or III, antibiotics, agents against malaria, H1 antihistamines, antipsychotics or medicinal products known to cause hypokalaemia or hypomagnesaemia) can lead to cardiac arrhythmias (see sections 4.4 and 4.8).

Chloral hydrate followed by intravenous furosemide may result in sweating, hot flushes and variable blood pressure including hypertension due to a hypermetabolic state caused by displacement of thyroid hormone from its bound state.

Delirium may occur, especially in the elderly, particularly when used in conjunction with psychotropics or anticholinergics.

In patients taking anticoagulants, when chloral hydrate is added to or withdrawn from the drug regimen, or its dosage changed, careful monitoring of the prothrombin time is required.

Chloral Hydrate may interfere with laboratory tests of thyroid function.

4.6. Fertility, pregnancy and lactation

Chloral Hydrate oral Solution should not be used in pregnancy and lactation.

Pregnancy

Little information is available on the possible adverse effects of chloral hydrate on human pregnancy. Chloral hydrate is known to cross the human placenta at term, but its use during relatively few pregnancies did not cause a detectable increase in abnormal outcomes. Some data suggest that prolonged administration of sedative doses of chloral hydrate to neonates increases the likelihood of hyperbilirubinemia.

Breast Feeding

Low levels of chloral hydrate have been found in breast milk. Although breastfeeding infants may be sedated by chloral hydrate in breast milk, the highest concentration measured in the milk (about 15 µg/ml) was considerably lower than that which would be measured in blood at a clinically active dose (100 µg/ml).

Fertility

There is no information relating to the effects of Chloral Hydrate Oral Solution on fertility.

4.7. Effects on ability to drive and use machines

Patients receiving Chloral Hydrate Oral Solution should be warned that their ability to drive or use machinery may be impaired by drowsiness.

4.8. Undesirable effects

The following adverse reactions have been reported. The frequency grouping is defined using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to

<1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).

Immune system disorders:

Not known: hypersensitivity, allergic skin reactions

Metabolism and nutrition disorders:

Not known: ketonuria

Psychiatric disorders:

Not known: anxiety, hyperactivity, confusion, tolerance, dependence, delirium, abuse, chronic intoxication, withdrawal symptoms

Nervous system disorders:

Not known: headache, ataxia

Respiratory, thoracic and mediastinal disorders:

Not known: dyspnoea, respiratory depression

Cardiac disorders:

Not known: QTc prolongation, arrhythmias (see sections 4.4 and 4.5)

Gastrointestinal disorders:

Not known: gastric irritation, abdominal distension, flatulence, gastric necrosis, gastric perforation, nausea, vomiting, gastritis

Renal and urinary disorders:

Not known: parenchymatous renal injury

Elderly patients

Ataxia, confusion, falls and injuries.

Paediatric population

In neonates and children <2 years of age, there is an increased risk of undesirable effects (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

The signs and symptoms of overdose involve the cardiovascular, respiratory and central nervous systems. These may include: respiratory depression, arrhythmias, hypothermia, pin-point pupils, hypotension or coma. Gastric irritation may result in vomiting and even gastric necrosis. If the patient survives, icterus due to hepatic damage and albuminuria from renal damage may appear. Serious problems have arisen with doses as little as 4g and 10g can be fatal. Overdosage should be treated with gastric lavage or inducing vomiting to empty the stomach. Supportive measures must be used.

Haemodialysis, and in some cases haemoperfusion, have been reported to be effective in promoting the clearance of trichloroethanol.

💬 Ask about this leaflet

Ask anything about Welldorm Elixir. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →